Quick Answer
MBX Biosciences, Inc. reported Net Income of -$86.97 million for fiscal year 2025.
MBX Biosciences, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$86.97M | -40.5% |
| 2024 | -$61.92M | -90.2% |
| 2023 | -$32.56M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$21.62M | -19.2% | -11.4% |
| June 30, 2025 | -$19.41M | -22.4% | +18.7% |
| March 31, 2025 | -$23.88M | -93.6% | -31.6% |
| September 30, 2024 | -$18.14M | -78.5% | -14.4% |
| June 30, 2024 | -$15.86M | -108.4% | -28.5% |
| March 31, 2024 | -$12.34M | -107.4% | -21.4% |
| September 30, 2023 | -$10.16M | — | -33.6% |
| June 30, 2023 | -$7.61M | — | -27.9% |
- MBX Biosciences, Inc. showed a decrease of -40.5% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, MBX Biosciences, Inc.’s net income has declined by 167.1% (from -$32.56 million to -$86.97 million).
- The most recent figure is from MBX Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: